EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
Rhea-AI Summary
NeuroSense Therapeutics (NASDAQ:NRSN) announced that patient community group EverythingALS will host an online event titled “PrimeC - Connecting the Dots” on June 24, 2026, at 7 pm ET.
The session will review emerging data on PrimeC for ALS, led by Prof. Jeffrey Rosenfeld, joined by NeuroSense CEO Alon Ben-Noon, and is aimed at people with ALS, families, caregivers, clinicians, and others interested in ALS research.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NRSN
On the day this news was published, NRSN declined 1.94%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $629K from the company's valuation, bringing the market cap to $31.81M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Patent grant | Positive | +1.1% | South Korean patent for PrimeC composition and ALS use protection to 2042. |
| Jun 09 | Patent grant | Positive | -0.2% | Japanese patent extending PrimeC composition and formulation protection through 2042. |
| Apr 28 | Financing | Positive | +7.8% | Insider-led PIPE raising $600,000 at a premium to market price. |
| Apr 06 | Patent grant | Positive | -8.2% | Brazilian patent granting PrimeC composition protection and supporting Phase 3 plans. |
| Mar 31 | Earnings update | Neutral | +3.3% | Year-end 2025 results with strong ALS data but very limited cash and net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NRSN news has triggered mixed reactions, with some positive patent and clinical updates met by both rallies and notable selloffs.
Key Terms
als medical
mnd medical
neuromuscular medical
biotechnology technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Event details:
Date: June 24, 2026
Time: 7 pm ET
Link for registration: Click Here
The session will be presented by Prof. Jeffrey Rosenfeld, MD, PhD, FAAN, Professor of Neurology and Director of the Neuromuscular ALS/MND Program at Loma Linda University School of Medicine. With more than 30 years caring for people with ALS and leading some of the most extensive multidisciplinary ALS programs in the country, Prof. Rosenfeld brings both the clinical depth and the bedside perspective to walk through what the latest findings show.
He'll be joined by Alon Ben-Noon, Co-Founder and CEO of NeuroSense Therapeutics, for the conversation that follows.
This is a conversation for people living with ALS, families, caregivers, clinicians, and anyone who wants to understand the latest developments in ALS research.
About NeuroSense
NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.
NeuroSense has received clearance from the
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/everythingals-to-host-neurosense-in-a-community-event-named-primec---connecting-the-dots-302806305.html
SOURCE NeuroSense